These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22711252)

  • 1. Comments on 'Sample size for equivalence trials: a case study from a vaccine lot consistency trial' by J. Ganju, A. Izu and A. Anemona.
    Sun X; Li X; Chen J
    Stat Med; 2012 Jul; 31(15):1652-3; author reply 1654. PubMed ID: 22711252
    [No Abstract]   [Full Text] [Related]  

  • 2. Comments on 'Sample size for equivalence trials: A case study from a vaccine lot consistency trial' by J. Ganju, A. Izu and A. Anemona, Statistics in Medicine 2008; 27:3743-3754.
    Kohberger RC
    Stat Med; 2009 Jan; 28(1):177-8, author reply 178-9. PubMed ID: 18937271
    [No Abstract]   [Full Text] [Related]  

  • 3. Sample size for equivalence trials: a case study from a vaccine lot consistency trial.
    Ganju J; Izu A; Anemona A
    Stat Med; 2008 Aug; 27(19):3743-54. PubMed ID: 18416439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical considerations for vaccine immunogenicity trials. Part 2: Noninferiority and other statistical approaches to vaccine evaluation.
    Plikaytis BD; Carlone GM
    Vaccine; 2005 Feb; 23(13):1606-14. PubMed ID: 15694513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comments on 'Use of composite endpoints in clinical trials' by Abdul J. Sankoh, Haihong Li and Ralph B. D'Agostino, Sr.
    Gómez G; Gómez-Mateu M
    Stat Med; 2016 Jan; 35(2):317-8. PubMed ID: 26767751
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA introductory comments: clinical studies design and evaluation issues.
    Woodcock J
    Clin Trials; 2005; 2(4):273-5. PubMed ID: 16281424
    [No Abstract]   [Full Text] [Related]  

  • 7. Statistical considerations for confirmatory clinical trials for similar biotherapeutic products.
    Njue C
    Biologicals; 2011 Sep; 39(5):266-9. PubMed ID: 21807534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Journal club 101 for the new practitioner: evaluation of a clinical trial.
    Askew JP
    Am J Health Syst Pharm; 2004 Sep; 61(18):1885-7. PubMed ID: 15487877
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical drug trials. 1: The 4 phases of clinical trials].
    Gleiter CH; Bieck PR
    Fortschr Med; 1991 Feb; 109(5):136-7. PubMed ID: 2045036
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of experimental design parameters on the determination of sample size.
    Jeffcoat M
    J Periodontal Res; 1992 Jul; 27(4 Pt 2):320-2. PubMed ID: 1507020
    [No Abstract]   [Full Text] [Related]  

  • 11. Blinded sample size re-estimation in three-arm trials with 'gold standard' design.
    Mütze T; Friede T
    Stat Med; 2017 Oct; 36(23):3636-3653. PubMed ID: 28608469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An alternative to the use of two-sided tests in clinical trials.
    Dunnett CW; Gent M
    Stat Med; 1996 Aug; 15(16):1729-38. PubMed ID: 8870155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars clinical development program: confirmatory clinical trials: a virtual/simulated case study comparing equivalence and non-inferiority approaches.
    Fletcher MP
    Biologicals; 2011 Sep; 39(5):270-7. PubMed ID: 21875812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lot consistency as an equivalence problem.
    Lachenbruch PA; Rida W; Kou J
    J Biopharm Stat; 2004 May; 14(2):275-90. PubMed ID: 15206526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical evaluation of drugs].
    Wasielewski S
    Med Monatsschr Pharm; 1992 Feb; 15(2):34. PubMed ID: 1579074
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical evaluation of new drugs].
    Lewis PJ
    Rev Prat; 1982 Sep; 32(41-42):2649-50 passim. PubMed ID: 7146802
    [No Abstract]   [Full Text] [Related]  

  • 17. [Protocol for the clinical pharmacology study of the hypnotic properties of a drug].
    Allain H; Milon D; van den Driessche J
    Therapie; 1984; 39(1):13-6. PubMed ID: 6463940
    [No Abstract]   [Full Text] [Related]  

  • 18. [General modality for evaluation of drugs in pediatry].
    Autret E
    Arch Fr Pediatr; 1990 Nov; 47(9):627-8. PubMed ID: 2078119
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA signals it's open to drug trials that shift midcourse.
    Mathews AW
    Wall St J (East Ed); 2006 Jul; ():B1, B8. PubMed ID: 16858817
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacodynamic modelling. Application to new drug development.
    Kroboth PD; Schmith VD; Smith RB
    Clin Pharmacokinet; 1991 Feb; 20(2):91-8. PubMed ID: 2029808
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.